SUPPLEMENTAL MATERIALS Online Table 1. Characteristics of

advertisement
SUPPLEMENTAL MATERIALS
Online Table 1. Characteristics of patients included in the analysis cohort compared with those excluded due to missing biomarker or outcome
data.
Excluded
(N=56)
Included
(N=427)
P-value
67 (50.5 - 77)
68 (58 - 78)
0.1585
Male sex
66
75
0.1552
White race
50
76
<0.0001
24 (16.5 - 46.5)
32 (20 - 55)
0.0087
Ejection fraction <50%
77
69
0.2417
New York Heart Association Class IV
29
35
0.3951
Hospitalization for HF in the past year
84
74
0.1004
Ischemic etiology
46
60
0.0580
Atrial fibrillation/flutter
45
54
0.1937
Diabetes mellitus
55
57
0.8256
Implantable cardioverter defibrillator
43
34
0.1892
ACE inhibitor or ARB
59
56
0.6510
Beta-blocker
79
82
0.5678
Aldosterone antagonist
34
25
0.1675
Nitrates
29
31
0.6691
Nitrates and hydralazine
14
11
0.5399
120 (80 - 160)
120 (80 - 160)
0.8644
201 (172 - 243)
209 (179 - 257)
0.4385
33.1 (26.9 - 38.2)
31.9 (26.9 - 38.4)
0.9750
115 (103 - 129)
114 (104 - 129)
0.8780
Variable
Age, years
Ejection fraction, %
Baseline Medications (at randomization)
Furosemide equivalent dose, mg/day
Physical Examination
Weight, lbs
BMI,
kg/m2
Systolic blood pressure, mmHg
1
Excluded
(N=56)
Included
(N=427)
P-value
74 (68.5 - 90.5)
76 (68 - 85)
0.8819
JVP ≥ 8 cm water
96
93
0.7592
Orthopnea
98
91
0.1606
Peripheral edema grade ≥ 2+
80
83
0.6692
PRA, ng/ml/h [mean ± SD]
4.1 (1.5 - 18.3)
5.0 (0.9 - 16.6)
0.7455
Aldosterone, pg/ml [mean ± SD]
194 (134 - 480)
211 (111 - 364)
0.4876
Sodium, mg/l
138 (135 - 141)
138 (135 - 141)
0.6449
Blood urea nitrogen, mg/dl
30.4 (19.5 - 50.5)
40.0 (25.5 - 57.0)
0.0076
Creatinine, mg/dl
1.25 (0.97 - 1.62)
1.70 (1.23 - 2.17)
0.0004
54.4 (36.8 - 66.9)
40.0 (29.4 - 56.6)
0.0002
5200 (3113 - 10305)
4307 (2273 - 9823)
0.3178
Variable
Heart rate, beats/min
Laboratories
Estimate glomerular filtration rate,
ml/min/1.73m2
NT-proBNP, pg/ml
Presented as % or median (IQR) unless otherwise noted.
Abbreviations: RAAS indicates renin-angiotensin-aldosterone system; PRA, plasma renin activity; HF, heart failure; ACE-I, angiotensin converting
enzyme inhibitor; ARB, angiotensin receptor blocker; JVP, jugular venous pressure; SD, standard deviation; NT-proBNP, N-terminal pro Brain
Natriuretic Peptide.
2
Online Table 2. RAAS levels based on baseline medication use.
Baseline PRA (ng/ml/hr)
N
Median
(25th, 75th percentile)
Yes
238
4.4 (0.5, 17.4)
No
189
5.4 (1.6, 14.8)
108
10.0 (3.4, 24.6)
Baseline Medication Use
Baseline Aldosterone (pg/ml)
p-value*
Median
(25th, 75th percentile)
p-value*
ACE-I/ARB
0.18
168 (93, 278)
283 (161, 494)
<0.001
Aldosterone antagonist
Yes
No
319
* P-values come from Wilcoxon rank sum tests.
3.2 (0.8, 14.0)
<0.001
327 (194, 551)
175 (100, 309)
<0.001
Abbreviations: ACE-I indicates angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; PRA, plasma renin activity, RAAS,
renin-angiotensin-aldosterone system.
OnlineTable 3. RAAS levels in patients with reduced (EF<50%) vs. preserved EF (≥50%) based on decongestion strategy.
Baseline Biomarker
Biomarker Change at
72 or 96 h
Baseline Biomarker
Biomarker Change at
72 or 96 h
Treatment
p-value
EF
p-value
0.0224
0.0427
0.6477
0.0542
0.0162
0.8731
0.5627
0.0128
0.7310
0.0148
0.9700
0.2209
PRA (ng/ml/h)
DOSE-AHF
Bolus Furosemide (N=110)
Continuous Infusion (N=96)
Reduced EF
5.9 (1.0, 21.2)
0.46 (-.25, 5.46)
5.0 (0.7, 15.3)
0.65 (-2.1, 7.79)
Preserved EF
2.5 (0.8, 15.2)
1.03 (-1.0, 6.11)
1.46 (0.63, 7.45)
3.5 (0.2, 15.4)
Low-dose Furosemide (N=95)
High-dose Furosemide (N=111)
Reduced EF
5.6 (0.9, 20.8)
0.48 (-1.6, 5.70)
5.6 (0.9, 18.4)
1.03 (-.26, 6.57)
Preserved EF
2.25 (0.78, 8.80)
3.8 (0.2, 16.4)
1.9 (0.6, 13.5)
1.04 (-.05, 6.11)
CARRESS
Stepped Pharmacologic Care (N=78)
Ultrafiltration (N=76)
Reduced EF
3.5 (0.9, 14.4)
0.72 (-1.3, 7.15)
5.7 (3.1, 12.7)
3.0 (-0.5, 13.5)
Preserved EF
3.8 (0.9, 14.8)
0.09 (-3.2, 1.30)
6.2 (1.7, 24.1)
4.6 (0.2, 14.8)
Aldosterone (pg/ml)
DOSE-AHF
Bolus Furosemide (N=113)
Continuous Infusion (N=102)
Reduced EF
241 (131, 400)
-2.0 (-89, 76.1)
165 (95, 343)
2 (-58, 104)
Preserved EF
149 (93, 321)
-7.3 (-102, 32.6)
200 (126, 362)
18 (-84, 106)
Low-dose Furosemide (N=102)
High-dose Furosemide (N=113)
Reduced EF
215 (110, 358)
8 (-54, 115)
201 (95, 364)
-6.0 (-91, 47.9)
Preserved EF
153 (93, 247)
31.3 (-78, 81.7)
154 (108, 352)
-11 (-105, 42.5)
CARRESS
Stepped Pharmacologic Care (N=79)
Ultrafiltration (N=76)
Reduced EF
271 (124, 375)
-4 (-112, 114)
264 (164, 485)
-28 (-161, 50.8)
Preserved EF
184 (98, 358)
34.9 (-77, 95.0)
175 (113, 282)
0.0 (-46, 93.4)
* P-values for treatment and EF effect come from linear regression models for 72 or 96 hour RAAS adjusted for baseline RAAS value, baseline
ACE/ARB use, and baseline aldosterone antagonist use where a log transformation is applied to both the baseline and follow-up RAAS measure.
Online Table 4. Net volume loss (ml) from baseline to 72 hours (DOSE-AHF) or 96 hours (CARRESS-HF) by decongestion strategy.
Treatment
Median
(25 , 75th percentile)
[ml]
th
p-value*
DOSE-AHF
Bolus dose furosemide
3700 (2012, 5875)
Continuous infusion furosemide
4151 (1872, 6180)
Low-dose furosemide
2912 (1714, 4880)
High-dose furosemide
4452 (2347, 7147)
0.94
0.005
CARRESS-HF
Ultrafiltration
7112 (4192, 10567)
Stepped pharmacologic therapy
6255 (3999, 9445)
* P-values come from Wilcoxon rank sum tests.
0.28
OnlineTable 5. Association between baseline RAAS biomarker quartile with time to death or HF hospitalization (reference=quartile 4).
RAAS marker
PRA
N
Events
427
134
Hazard Ratio* (95% CI)
0.40
Quartile 1
0.73 (0.44, 1.22)
Quartile 2
0.68 (0.42, 1.08)
Quartile 3
0.81 (0.51, 1.29)
Quartile 4
1.00
Aldosterone
427
p-value
134
0.29
Quartile 1
0.64 (0.38, 1.09)
Quartile 2
0.82 (0.50, 1.35)
Quartile 3
1.03 (0.65, 1.62)
Quartile 4
1.00
*Hazard ratio adjusted for trial, and baseline ACE-inhibitor/ARB and aldosterone antagonist use.
Download
Random flashcards
Pastoralists

20 Cards

Radioactivity

30 Cards

Marketing

46 Cards

African nomads

18 Cards

Ethnology

14 Cards

Create flashcards